ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00268892
Recruitment Status : Completed
First Posted : December 23, 2005
Results First Posted : December 6, 2010
Last Update Posted : December 24, 2010
Sponsor:
Information provided by:
Ferring Pharmaceuticals

Brief Summary:
The purpose of this extension study was to collect long-term safety and tolerability information to support a marketing authorisation application for a three-month dosage regimen of degarelix.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Degarelix Phase 2 Phase 3

Detailed Description:
The data include data from the participants who participated in both the main study FE200486 CS15 (NCT00113753) and the extension study FE200486 CS15A.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 278 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens in Patients With Prostate Cancer
Study Start Date : January 2006
Actual Primary Completion Date : September 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Degarelix
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Degarelix 240/240@40(1-3-6-9)
Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (40 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (40 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
Drug: Degarelix

Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).

Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.

Other Name: FE200486
Experimental: Degarelix 240/240@60(1-3-6-9)
Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
Drug: Degarelix

Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).

Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.

Other Name: FE200486
Experimental: Degarelix 240/240@60(1-4-7-10)
Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 4, 7, 10) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
Drug: Degarelix

Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).

Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.

Other Name: FE200486



Primary Outcome Measures :
  1. Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight [ Time Frame: Baseline and up to 4.5 years ]
    This outcome measure included incidence of markedly abnormal values in blood pressure (systolic and diastolic), pulse, and body weight during the trial. The table presents the number of participants with a normal baseline value and at least one post-baseline markedly abnormal value.

  2. Liver Function Tests [ Time Frame: 4.5 years ]
    The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases >3x ULN and ALT increases >3x ULN with concurrently increased bilirubin >1.5 ULN.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has given written consent prior to any study-related activity is performed. A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient.
  • Has successfully completed the main study.

Exclusion Criterion:

- Has been withdrawn from the main study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00268892


Locations
Belgium
UZ Gasthuisberg Leuven
Leuven, Belgium
Finland
Helsinki University Hospital, Maria Hospital, Building 11
Helsinki, Finland
Central Hospital, North Karelian
Joensuu, Finland
Oulu University Hospital
Oulu, Finland
Tampere University Hospital
Tampere, Finland
France
Fédération d'Urologie et Néphrologie, BP69 Hôpital Pasteur
Nice, France
Germany
Gemeinschaftspraxis Dres Effert und Benedic
Aachen, Germany
Montenegro
Clinical Center Novi Sad, Clinic of Urology
Novi Sad, Montenegro
Netherlands
Academic Medical Center, Urology
Amsterdam, Netherlands
St. Elisabeth Hospital
Tilburg, Netherlands
Romania
"Centrul Medical Privat" Prof. Dr. Ioiart Ioan"
Arad, Romania
Clinical Hospital "Prof. Dr. Theodor Burghele", Urology Department
Bucharest, Romania
University CF Hospital No. 2
Bucharest, Romania
Russian Federation
Andros Clinic
St. Petersburg, Russian Federation
City Hospital #15
St. Petersburg, Russian Federation
City Hospital #26
St. Petersburg, Russian Federation
Pavlov State Medical University, Outpatient Diagnostic Center affiliated with the Urology Department
St. Petersburg, Russian Federation
Pavlov State Medical University, Urology Department
St. Petersburg, Russian Federation
Serbia
Clinical Center of Serbia, Institute of Urology and Nephrology
Belgrade, Serbia
United Kingdom
Mount Vernon Cancer Centre, Marie Cuire Research Wing
Northwood, Middlesex, United Kingdom
Castle Hill Hospital
Hull, North Humberside, United Kingdom
Ward 13, NHS Forth Valley Acute Operating Division, Falkirk and District Royal Infirmary, Majors Loans
Falkirk, United Kingdom
Level 7, Urology Research Unit, Derriford Hospital
Plymouth, United Kingdom
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Study Director: Clinical Development Support Ferring Pharmaceuticals

Responsible Party: Clinical Development Support, Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00268892     History of Changes
Other Study ID Numbers: FE200486 CS15A
First Posted: December 23, 2005    Key Record Dates
Results First Posted: December 6, 2010
Last Update Posted: December 24, 2010
Last Verified: December 2010

Keywords provided by Ferring Pharmaceuticals:
Prostate Cancer
Androgen ablation therapy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases